(P < 1 × 10−300, Nagelkerke r2 = 0.12; Supplementary Table 2), confirming the validity of combining the datasets. For comparison with other studies, we also report polygenic variance on the liability scale68, which amounted to 5.7% for CLOZUK at the 0.05 P-value threshold (Supplementary Table 2). As in the PGC study, the limited r2 and area under the receiver operating characteristic curve (AUROC) obtained by this analysis restrict the current clinical utility of these scores in schizophrenia.
